Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons

References

• Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA. 2008 Nov 26;300(20):2417–2419.
   PubMed Web of Science ®Google Scholar
• Hammad TA, Neyarapally GA, Iyasu S, et al. The future of population-based postmarket drug risk assessment: a regulator’s perspective. Clin Pharmacol Ther. 2013 Sep;94(3):349–358.
   PubMed Web of Science ®Google Scholar
• Stanley K. Design of randomized controlled trials. Circulation. 2007 Mar 6;115(9):1164–1169.
   PubMed Web of Science ®Google Scholar
• Singal AG, Higgins PDR, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014;5:e45.
   PubMed Web of Science ®Google Scholar
• Curtin F, Schulz P. Assessing the benefit: risk ratio of a drug–randomized and naturalistic evidence. Dialogues Clin Neurosci. 2011;13(2):183–190.
   PubMedGoogle Scholar
• Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials. 2012 Aug;20(13):138.
   Web of Science ®Google Scholar
• Zorzela L, Golder S, Liu Y, et al. Quality of reporting in systematic reviews of adverse events: systematic review. BMJ. 2014 Jan;8(348):f7668.
   Google Scholar
• Alves C, Batel-Marques F, Macedo AF. Data sources on drug safety evaluation: a review of recent published meta-analyses. Pharmacoepidemiol Drug Saf. 2012 Jan;21(1):21–33.
   PubMed Web of Science ®Google Scholar
• Alves C, Macedo AF, Marques FB. Sources of information used by regulatory agencies on the generation of drug safety alerts. Eur J Clin Pharmacol. 2013 Dec;69(12):2083–2094.
   PubMed Web of Science ®Google Scholar
• Alves C, Marques FB, Macedo AF. Drug-safety alerts issued by regulatory authorities: usefulness of meta-analysis in predicting risks earlier. Eur J Clin Pharmacol. 2014 Jun;70(6):745–756.
   PubMed Web of Science ®Google Scholar
• Loke YK, Price D, Herxheimer A and Group. Cochrane adverse effects methods. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol. 2007 Jul;5(7):32.
   Web of Science ®Google Scholar
• Golder S, Loke YK, Bland M. Comparison of pooled risk estimates for adverse effects from different observational study designs: methodological overview. PLoS One. 2013 Aug 20;8(8):e71813.
   PubMed Web of Science ®Google Scholar
• FDA. Structured approach to benefit-risk assessment in drug regulatory decision-making. Draft patient drug user free act (PDUFA) I implementation plan. [Online] 2013. [cited 2015 Sep 15]. http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM329758.pdf.
   Google Scholar
• EMA. European Medicines Agency recommends suspension of Avandia. Avandamet and Avaglim—anti-diabetes medication to be taken off the market [Press release]. [Online]. 2010 Sep 23. [cited 2015 Apr 23]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&mid=WC0b01ac058004d5c1
   Google Scholar
• FDA. FDA drug safety communication: updated risk evaluation and mitigation strategy (REMS) to restrict access to rosiglitazone containing medicines including Avandia, Avandamet, and Avandaryl [Press release]. [Online]. 2011 May 18. [cited 2015 Apr 23]. http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm#Safety_Announcement
   Google Scholar
• Mendes D, Alves C, Batel-Marques F. Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone. Pharmacoepidemiol Drug Saf. 2015 Dec;24(12):1259–1270.
   PubMed Web of Science ®Google Scholar
• EMA. Benefit-Risk Methodology Project. Development and testing of tools and processes for balancing multiple benefits and risks as an aid to informed regulatory decisions about medicinal products. [Online]. 2009. [cited 2015 Sep 15]. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/07/WC500109477.pdf.
   Google Scholar
• Mt-Isa S, Hallgreen CE, Wang N, et al. Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):667–678.
   PubMed Web of Science ®Google Scholar
• Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988 Jun 30; 318(26):1728–1733.
   PubMed Web of Science ®Google Scholar
• Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995 Feb 18;310(6977):452–454.
   PubMed Web of Science ®Google Scholar
• Straus SE, Glasziou P, Richardson WS, et al. Evidence-based medicine: how to practice and teach it. London: Churchill Livingstone; 2011. p. 77–97.
   Google Scholar
• Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013 May;67(5):407–411.
   PubMed Web of Science ®Google Scholar
• Citrome L. Relative vs. absolute measures of benefit and risk: what’s the difference? Acta Psychiatr Scand. 2010 Feb;121(2):94–102.
   PubMed Web of Science ®Google Scholar
• Deeks JJ, Higgins JPT, Altman DG, et al. Chapter 9: analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration; 2011. [updated Mar]. Available from: http://handbook.cochrane.org
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials.Control. Clin Trials. 1986 Sep;7(3):177–188.
   Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analysis. BMJ. 2003 Sep 6;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998 Nov 7;317(7168):1309–1312.
   PubMed Web of Science ®Google Scholar
• EMA. Almitrine Article-31 referral - PRAC assessment report. [Online]. 2013 Jun 10. [cited 2016 Feb 09] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Almitrine/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500144134.pdf
   Google Scholar
• Arnaud F, Bertrand A, Charpin J, et al. Long term almitrine bismesylate treatment in patients with chronic bronchitis and emphysema: a multicentre double-blind placebo controlled study. Eur J Respir Dis Suppl. 1983;126:323–336.
   PubMedGoogle Scholar
• Voisin C, Howard P, Ansquer JC. Almitrine bismesylate: a long-term placebo-controlled double-blind study in COAD–vectarion international multicentre study group. Bull Eur Physiopathol Respir. 1987 Aug;23(Suppl 11):169s–182s.
   PubMedGoogle Scholar
• Bakran I, Vrhovac B, Stangl B, et al. Double-blind placebo controlled clinical trial of almitrine bismesylate in patients with chronic respiratory insufficiency. Eur J Clin Pharmacol. 1990;38(3):249–253.
   PubMed Web of Science ®Google Scholar
• Bardsley PA, Howard P, DeBacker W, et al. Two years treatment with almitrine bismesylate in patients with hypoxic chronic obstructive airways disease. Eur Respir J. 1991 Mar;4(3):308–310.
   PubMed Web of Science ®Google Scholar
• Weitzenblum E 1, Arnaud F, Bignon J, et al. [Sequential administration of a reduced dose of almitrine to patients with chronic obstructive bronchopneumopathies. A controlled multicenter study]. Rev Mal Respir. 1992;9(4):455–463. [French].
   PubMed Web of Science ®Google Scholar
• Bardsley PA, Howard P, Tang O, et al. Sequential treatment with low dose almitrine bismesylate in hypoxaemic chronic obstructive airways disease. Eur Respir J. 1992 Oct;5(9):1054–1061.
   PubMed Web of Science ®Google Scholar
• Górecka D, Sliwiński P, Pałasiewicz G, et al. Effects of almitrine bismesylate on arterial blood gases in patients with chronic obstructive pulmonary disease and moderate hypoxaemia: a multicentre, randomised, double-blind, placebo-controlled study. Respiration. 2003 May-Jun;70(3):275–283.
   PubMed Web of Science ®Google Scholar
• Derumeaux G, Ernande L, Serusclat A, et al. REGULATE trial investigators. Echocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitus. PLoS One. 2012;7(6):e38273.
   PubMed Web of Science ®Google Scholar
• Weill A, Païta M, Tuppin P, et al. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf. 2010 Dec;19(12):1256–1262.
   PubMed Web of Science ®Google Scholar
• EMA. Benfluorex - Article 107 referral - Annex II. [Online]. 2011 Jul 27. [cited 2016 Feb 09]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Benfluorex_107/WC500109589.pdf
   Google Scholar
• EMA. CHMP Assessment Report For Tredaptive. International Nonproprietary Name: nicotinic acid /laropiprant. Procedure No. EMEA/H/C/889. 2008. [cited 2016 May 03]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000889/WC500042219.pdf
   Google Scholar
• Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2008 Dec;62(12):1959–1970.
   PubMed Web of Science ®Google Scholar
• Gleim G, Ballantyne CM, Liu N, et al. Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br J Cardiol. 2009;16:90–97.
   Google Scholar
• Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009 Jul 1;104(1):74–81.
   PubMed Web of Science ®Google Scholar
• HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014 Jul 17;371(3):203–212.
   PubMed Web of Science ®Google Scholar
• EMA. CHMP Assessment Report for Tredaptive (Doc.Ref.: EMEA/348364/2008). [Online]. 2008. [cited 2016 Feb 09]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000889/WC500042219.pdf
   Google Scholar
• EMA. European Medicines Agency confirms recommendation to suspend Tredaptive, Pelzont and Trevaclyn [Press Release]. [Online]. 2013 Jan 18. [cited 2016 Feb 09]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/01/news_detail_001694.jsp&mid=WC0b01ac058001d126
   Google Scholar
• EMA. Acomplia European Public Assessment Report – Scientific Discussion. [Online]. 2006. [cited 2015 Sep 15]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000666/WC500021284.pdf
   Google Scholar
• Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005 Apr 16-22;365(9468):1389–1397.
   PubMed Web of Science ®Google Scholar
• Després J-P, Golay A, Sjöström L. Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005 Nov 17;353(20):2121–2134.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006 Feb 15;295(7):761–775.
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006 Nov 11;368(9548):1660–1672.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008 Apr 2;299(13):1547–1560.
   PubMed Web of Science ®Google Scholar
• EMA. Assessment Report For Acomplia. International Nonproprietary Name: rimonabant. Procedure No. EMEA/H/C/000666/A20/0012. 2009. [cited 2016 May 03]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000666/WC500021280.pdf
   Google Scholar
• FDA. Drug Approval Package: Vioxx (Rofecoxib) NDA# 021042 & 021052. [cited 2016 May 3]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/021042_52_Vioxx.cfm
   Google Scholar
• Ehrich EW, Bolognese JA, Watson DJ, et al. Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis. Am J Manag Care. 2001 Jun;7(6):609–616.
   PubMed Web of Science ®Google Scholar
• Saag K, Van Der Heijde D, Fisher C, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group. Arch Fam Med. 2000 Nov-Dec;9(10):1124–1134.
   PubMedGoogle Scholar
• Truitt KE, Sperling RS, Ettinger WH Jr, et al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging (Milano). 2001 Apr;13(2):112–121.
   PubMedGoogle Scholar
• Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology. 1999 Oct;117(4):776–783.
   PubMed Web of Science ®Google Scholar
• Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum. 2000 Feb;43(2):370–377.
   PubMed Web of Science ®Google Scholar
• Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum. 2000 May;43(5):978–987.
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005 Mar 17;352(11):1092–1102.
   PubMed Web of Science ®Google Scholar
• EMA. Avandia. EPAR - Scientific Discussion. 2006. [cited 2016 May 03]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000268/WC500029103.pdf
   Google Scholar
• Gsk-clinicalstudyregister.com. 2016. GSK Clinical Study Register. [online]. [cited 2016 May 3]. Available from: http://www.gsk-clinicalstudyregister.com/
   Google Scholar
• EMA. Avandia-H-C-268-A20-75: EPAR - Assessment Report (Doc.Ref.: EMA/831385/2010). [Online]. 2010. [cited 2016 Feb 09]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000268/WC500100757.pdf
   Google Scholar
• Food and Drug Administration. FDA Briefing Document. Advisory committee meeting for NDA 21071 Avandia (rosiglitazone maleate) tablet. 2010 July 13 and 14. [cited 2015 Sep 15]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM218493.pdf
   Google Scholar
• Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010 Jul 26;170(14):1191–1201.
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009 Jun 20;373(9681):2125–2135.
   PubMed Web of Science ®Google Scholar
• Brownstein JS, Murphy SN, Goldfine AB, et al. Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. Diabetes Care. 2010 Mar;33(3):526–531.
   PubMed Web of Science ®Google Scholar
• Ziyadeh N, McAfee AT, Koro C, et al. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database. Clin Ther. 2009 Nov;31(11):2665–2677.
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Lipscombe LL, et al. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ. 2009 Aug;18(339):b2942.
   Google Scholar
• Winkelmayer WC, Setoguchi S, Levin R, et al. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med. 2008 Nov 24;168(21):2368–2375.
   PubMed Web of Science ®Google Scholar
• Walker AM, Koro CE, Landon J. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):760–768.
   PubMed Web of Science ®Google Scholar
• Gerrits CM, Bhattacharya M, Manthena S, et al. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1065–1071.
   PubMed Web of Science ®Google Scholar
• EMA. Scientific Conclusions - Overall Summary Of The Scientific Evaluation Of Sibutramine Containing Medicinal Products. 2000. [cited 2016 May 03]. Available from: http://ec.europa.eu/health/documents/community-register/2001/200103264189/anx_4189_en.pdf
   Google Scholar
• Smith IG, Goulder MA. Sibutramine clinical study 1047 team. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract. 2001 Jun;50(6):505–512.
   PubMed Web of Science ®Google Scholar
• James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine trial of obesity reduction and maintenance. Lancet. 2000 Dec 23-30;356(9248):2119–2125.
   PubMed Web of Science ®Google Scholar
• Apfelbaum M, Vague P, Ziegler O, et al. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med. 1999 Feb;106(2):179–184.
   PubMed Web of Science ®Google Scholar
• Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA. 2001 Sep 19;286(11):1331–1339.
   PubMed Web of Science ®Google Scholar
• Kaukua JK, Pekkarinen TA, Rissanen AM. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. Int J Obes Relat Metab Disord. 2004 Apr;28(4):600–605.
   PubMed Web of Science ®Google Scholar
• McNulty SJ, Ur E, Williams G. Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care. 2003 Jan;26(1):125–131.
   PubMed Web of Science ®Google Scholar
• James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010 Sep 2;363(10):905–917.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Arfwidsson AC, Frison L, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. Thromb Haemost. 2002 Feb;87(2):231–237.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Bergqvist D, Kälebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet. 2002 Nov 9;360(9344):1441–1447.
   PubMed Web of Science ®Google Scholar
• Dahl OE, Eriksson BI, Agnelli G, et al. Postoperative melagatran/Ximelagatran for the prevention of venous thromboembolism following major elective orthopaedic surgery: effects of timing of first dose and risk factors for thromboembolism and bleeding complications on efficacy and safety. Clin Drug Invest. 2005;25(1):65–77.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost. 2003 Feb;89(2):288–296.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Agnelli G, Cohen A, et al. Significantly lower need for blood transfusions associated with post-operatively initiated subcutaneous melagatran/oral ximelagatran compared with enoxaparin. Thromb Haemost. 2004 Aug;92(2):428–430.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost. 2003 Dec;1(12):2490–2496.
   PubMed Web of Science ®Google Scholar
• Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003 Oct 30;349(18):1703–1712.
   PubMed Web of Science ®Google Scholar
• Colwell CW Jr, Berkowitz SD, Lieberman JR, et al. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am. 2005 Oct;87(10):2169–2177.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Eriksson BI, Cohen AT, et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res. 2009;123(3):488–497.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Letter: Withdrawal of Ximelagatran 36 mg film-coated tablets: EMEA/H/C/000702. 2006. [cited 2016 May 03]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/01/WC500069726.pdf
   Google Scholar
• Center for Behavioral Health Statistics and Quality. 2015. Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50). [cited 2016 May 3]. Available from: http://www.samhsa.gov/data/
   Google Scholar
• Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013 Jul 11;369(2):145–154.
   PubMed Web of Science ®Google Scholar
• De Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004 Jul;58(1):71–80.
   PubMed Web of Science ®Google Scholar
• Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the ‘number needed to treat’? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol. 2002 Feb;31(1):72–76.
   PubMed Web of Science ®Google Scholar
• Whalen J. FDA Panel Rejects Sanofi Drug for Obesity. WSJ. 2007. [cited 2015 Sep 15]. Available from: http://www.wsj.com/articles/SB118174200915533871
   Google Scholar
• European Medicines Agency. EMEA statement following withdrawal of Vioxx (rofecoxib) [Press release]. [cited 2015 Sep 15]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500015262.pdf
   Google Scholar
• Jüni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004 Dec 4-10;364(9450):2021–2029.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al.. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000 Nov 23;343(21):1520–8, 2 p following 1528.
   PubMed Web of Science ®Google Scholar
• Blind E, Dunder K, De Graeff P, et al. Rosiglitazone: a European regulatory perspective. Diabetologia. 2010;54:213–218. doi:10.1007/s00125-010-1992-5.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457–2471.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA Briefing Document. Readjudication of the rosiglitazone evaluated for cardiovascular outcomes and regulation of glycemia in diabetes trial (RECORD). Joint meeting of the endocrinologic and metabolic drugs advisory committee and the drug safety and risk management advisory committee. 2013 Jun 5–6. cited 2015 Sep 15. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM354859.pdf
   Google Scholar
• Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010 Jul 28;304(4):411–418.
   PubMed Web of Science ®Google Scholar
• EMA. Scientific conclusions - Overall summary of the scientific evaluation of sibutramine containing medicinal products. [Online]. 2001. [cited 2016 Feb 09]. http://ec.europa.eu/health/documents/community-register/2001/200103264189/anx_4189_en.pdf
   Google Scholar
• Franklin SS, Wong ND. Hypertension and cardiovascular disease: contributions of the framingham heart study. Glob Heart. 2013 Mar;8(1):49–57.
   PubMedGoogle Scholar
• FDA. Division of Cardiovascular and Renal Drug. NDA 21-686. Ximelagatran (H376/95). [Online]. 2004. [cited 2016 Feb 09]. http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4069B1_06_FDA-Backgrounder-C-R-MOR.pdf
   Google Scholar
• Astrazeneca. Exanta (ximelagatran) receives first approval. [Online]. 2003. [cited 2015 Nov 05]. http://195.69.152.75/Media/Press-releases/Article/20031223–EXANTA-XIMELAGATRAN-RECEIVES-FIRST-APPROVAL
   Google Scholar
• Medscape. FDA panel not convinced by ximelagatran. [Online]. 2004. [cited 2015 Sep 15]. http://www.medscape.com/viewarticle/782827
   Google Scholar
• Food and Drug Administration. CDER-PHRMA-AASLD Conference 2000. Clinical White Paper. 2000. [cited 2015 Sep 15]. Available from: http://www.fda.gov/downloads/drugs/scienceresearch/researchareas/ucm091457.pdf
   Google Scholar
• Baglin T. Communicating benefit and risk. Br J Haematol. 2009 Jun;146(1):31–33.
   PubMed Web of Science ®Google Scholar
• McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997 May 1;126(9):712–720.
   PubMed Web of Science ®Google Scholar
• Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses–sometimes informative, usually misleading. BMJ. 1999 Jun 5;318(7197):1548–1551.
   PubMed Web of Science ®Google Scholar
• EMA. Questions and answers on the recommendation to suspend the marketing authorisation of Acomplia (rimonabant) [Online]. 2008. [cited: 2016 May 02]. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500014779.pdf
   Google Scholar
• Hughes S, Cohen D, Jaggi R. Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study. BMJ Open. 2014 Jul 9;4(7):e005535.
   PubMed Web of Science ®Google Scholar
• Doshi P, Jefferson T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open. 2013 Feb 26;3(2):pii: e002496.
   PubMedGoogle Scholar
• Golder S, Loke YK. Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies? Br J Clin Pharmacol. 2008 Dec;66(6):767–773.
   PubMed Web of Science ®Google Scholar
• Potthast R, Vervölgyi V, McGauran N, et al. Impact of inclusion of industry trial results registries as an information source for systematic reviews. PLoS One. 2014 Apr 17;9(4):e92067.
   PubMed Web of Science ®Google Scholar